Public Policy
In the wake of the Supreme Court decision on Rutledge vs. PCMA, states have introduced legislation threatening ERISA pre-emption for employer-sponsored health plans. More
Briefing
“Public Policy”
15 result(s)
Public Policy
ACA Returns to Court
The California vs. Texas case before the U.S. Supreme Court could help determine the future of the Affordable Care Act (ACA), and could lead to one of several different results. More
Commentary
Public Policy
If ERISA pre-emption is not upheld for self-funded ERISA plans using PBMs to administer prescription drug benefits, we believe the implications may create unsustainable complexity... More
Commentary
Public Policy
With a slate of bills trying to tackle rising drug prices, CVS Health advocates for those that could help increase competition and lower drug prices; others may limit private... More
Commentary
Cost Management
New GAO report shows that rebates negotiated on behalf of payors may help control premiums and provides further proof of the value PBMs bring to payors and members. More
Commentary
Cost Management
Dynamic forces are affecting health and pharmacy care, affordability, and access. CVS Health is aligning efforts to address these challenges with... More
Video
Public Policy
Our perspective offered to Congress on solutions and policies that can help bring escalating drug prices under control. More
Commentary
Cost Management
A Guaranteed Net Cost model can adapt to evolving market trends and help payors stay ahead of manufacturer strategies such as authorized generics, and changing legislative... More
Briefing
Public Policy
Solutions such as POS rebates and $0 copay drug lists can lower costs for plans and consumers, while a one-size-fits-all approach could lead to unintended consequences, and higher... More
Briefing
Public Policy
Proposed HHS rule would eliminate rebates PBMs negotiate for Part D plans and MCOs, and may eventually affect all plans. Manufacturers would retain 15% of rebates currently... More
Briefing